Literature DB >> 2844553

Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists.

T S Shippenberg1, A Herz.   

Abstract

An unbiased place preference conditioning procedure was used to: (i) characterize the motivational effects of dopamine (DA)-receptor antagonists and (ii) examine the role of D-1 versus D-2 DA receptors in mediating the reinforcing and aversive properties of opioids. Acute administration of the D-1 antagonist, SCH 23390 (0.001-0.5 mg/kg), produced conditioned place aversions. In contrast, the D-2 antagonists, (-)-sulpiride and spiperone, were motivationally neutral, lacking reinforcing or aversive effects. Chronic infusion of SCH 23390 (1.0 mg/kg per day) during the conditioning sessions abolished the reinforcing effect of the mu-opioid agonist, morphine, and the place aversions produced by the kappa-opioid agonist, U-69593, and the opioid antagonist, naloxone. D-2 antagonists were ineffective in modifying the motivational properties of opioid agonists and naloxone. These data demonstrate the involvement of D-1 but not D-2 receptors in the motivational properties of opioids and suggest that the D-1 receptor is critical for the expression of reinforcing and aversive motivational states.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844553     DOI: 10.1016/0014-2999(88)90803-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

2.  Morphine-conditioned single-trial place preference: role of nucleus accumbens shell dopamine receptors in acquisition, but not expression.

Authors:  Sandro Fenu; Liliana Spina; Emilia Rivas; Rosanna Longoni; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-05-25       Impact factor: 4.530

3.  Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists.

Authors:  T S Shippenberg; R Bals-Kubik; A Huber; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 4.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

5.  Cellular sites for activation of delta-opioid receptors in the rat nucleus accumbens shell: relationship with Met5-enkephalin.

Authors:  A L Svingos; C L Clarke; V M Pickel
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

Review 6.  Biochemical and behavioural properties of clozapine.

Authors:  D M Coward; A Imperato; S Urwyler; T G White
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Evaluation of the interaction of mu and kappa opioid agonists on locomotor behavior in the horse.

Authors:  K R Mama; P J Pascoe; E P Steffey
Journal:  Can J Vet Res       Date:  1993-04       Impact factor: 1.310

8.  Long-lasting effects of adolescent oxycodone exposure on reward-related behavior and gene expression in mice.

Authors:  Victoria Sanchez; Marco D Carpenter; Nicole L Yohn; Julie A Blendy
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

9.  Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion.

Authors:  Minoru Narita; Keisuke Mizuo; Hirokazu Mizoguchi; Mamoru Sakata; Michiko Narita; Leon F Tseng; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

10.  Morphine withdrawal aggression: modification with D1 and D2 receptor agonists.

Authors:  J W Tidey; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.